− Achieved global recognition and Top Employer certification in 39 countries from the Top Employers Institute®
− Recognition underscores Takeda’s unwavering commitment to its people
OSAKA, Japan & CAMBRIDGE, Mass., January 20, 2022–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) (“Takeda”) today announced that it has been one of only 11 companies to achieve Global Top Employer® Certification for 2022, marking the fifth consecutive year that it has been recognized for its outstanding workplace policies and practices. of human resources worldwide. In addition to global certification, Takeda is also recognized as a Top Employer in four regions and 39 countries, reinforcing its unwavering commitment to creating a diverse and inclusive organization that enables its employees to thrive.
Established over 30 years ago, the Top Employers Institute program certifies organizations based on participation and the results of their survey of HR best practices. The survey covers all aspects of HR and employee-centric practices, including: HR strategy, work environment, talent acquisition, learning, well-being, engagement, diversity and inclusion, etc.
“It is an honor to be recognized by the Top Employer Institute for the fifth consecutive year as we continue to navigate highly dynamic and evolving workplaces around the world,” said Lauren Duprey, Director of Resources Takeda human resources. “Over the past decade, Takeda has transformed into a leading global biopharmaceutical company dedicated to creating better health for people and a better future for the world, and our success – now and in the future. the future – is driven by our people. As we look to the future, we will continue to build an organization that fosters collaboration and innovation among people from all walks of life so they can reach their full potential.”
Top Employers Institute CEO David Plink said, “As we reflect on another challenging year for employers and employees, Takeda continues to demonstrate its holistic commitment to employees globally and locally. We congratulate Takeda for another consecutive year as a Global Best Employer certification.”
Takeda has excelled globally in the areas of ethics and integrity, values, business strategy, organization and change, and employer brand. Each of the 39 Takeda countries that participated in the Top Employer survey received certification, with two countries receiving certification for the first time. The full list of countries where Takeda has been named Top Employer is below:
Asia Pacific: Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan and Thailand
Europe: Austria, France, Germany, Ireland, Italy, Kazakhstan, Poland, Portugal, Romania, Russia, Serbia, Spain, Switzerland, Turkey, United Kingdom and Ukraine
Latin America: Argentina, Brazil, Colombia, Ecuador, Mexico and Peru
Middle East: Israel, Saudi Arabia and United Arab Emirates
North America: United States
To learn more about the Top Employers Institute and the Top Employers certification, visit: https://www.top-employers.com.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader, headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided through our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: oncology, rare genetics and hematology, neurosciences and gastroenterology (GI). We also make targeted R&D investments in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by pushing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust pipeline and diversified in terms of modalities. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) relating to this release. This press release (including any oral presentation and any Q&As relating thereto) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer for purchase, otherwise acquire, subscribe, exchange, sell or otherwise dispose of securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are offered to the public by means of this press release. No offer of securities will be made in the United States except pursuant to registration under the US Securities Act of 1933, as amended, or an exemption therefrom. This press release is given (together with any other information which may be provided to the recipient) on the condition that it is to be used by the recipient for informational purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly hold investments are separate entities. In this press release, “Takeda” is sometimes used for convenience when referring to Takeda and its affiliates generally. Similarly, the words “we”, “us” and “our” are also used to refer to affiliates in general or the people who work for them. These expressions are also used when it is not useful to identify the particular company or companies.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20220119005654/en/
+81 (0) 3-3278-3414
American and international media